Cargando…
Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT
In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). A total of 30 patient...
Autores principales: | Farnebo, Jacob, Wadelius, Agnes, Sandström, Per, Nilsson, Sten, Jacobsson, Hans, Blomqvist, Lennart, Ullén, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/ https://www.ncbi.nlm.nih.gov/pubmed/27495034 http://dx.doi.org/10.1097/MD.0000000000004308 |
Ejemplares similares
-
Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2014) -
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
por: Farnebo, Jacob, et al.
Publicado: (2014) -
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014) -
Abiraterone Acetate
Publicado: (2012) -
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)